← Back to all trials
Recruiting
NCT07151703
Topical Versus Injection PRP for Olfactory Dysfunction
Conditions: Olfactory Dysfunction, Anosmia, Hyposmia
Sex: All
Ages: 18 Years – 80 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 60
Sponsor: Taipei Veterans General Hospital, Taiwan
Location: Taipei Veterans General Hospital Taipei
Summary
The goal of this clinical trial is to determine whether two different delivery methods of autologous platelet-rich plasma (PRP) can improve olfactory function in adults with persistent olfactory dysfunction lasting more than three months. The main questions it aims to answer are:
1. Does carrier-assisted topical application of PRP lead to comparable or better improvement in smell function than intranasal injection of PRP?
2. Which method provides greater patient comfort and fewer adverse effects?
Researchers will compare carrier-assisted topical PRP application to intranasal PRP injection to see if one approach is more effective in restoring olfactory function.
Participants will:
1. Receive a single PRP treatment delivered either by injection or via a PRP-soaked carrier placed into the olfactory cleft.
2. Continue daily olfactory training for three months following the intervention.
3. Undergo smell testing (Sniffin' Sticks) before and after treatment and complete quality-of-life questionnaires.
Eligibility Criteria
Inclusion Criteria:
* Aged between 18 and 80 years, regardless of sex
* Subjective complaint of olfactory dysfunction with confirmed hyposmia or anosmia based on standardized olfactory testing
* History of at least 3 months of prior olfactory training but with persistent olfactory complaints
Exclusion Criteria:
* Congenital anosmia
* Diagnosed neurological or structural brain abnormalities (e.g., brain tumor, major head trauma, stroke) with low likelihood of olfactory recovery
* Inability or unwillingness to comply with study procedures or follow-up assessments
Source: ClinicalTrials.gov (NCT07151703). StuddyBuddy aggregates publicly available trial information.